Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy
| Autor: | Janice Mooney, Richard A. Watts, Eleana Ntatsaki, David G. I. Scott |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Pediatrics Population Rheumatoid Vasculitis Young Adult Rheumatology Internal medicine Necrotizing Vasculitis medicine Humans Pharmacology (medical) education Aged Retrospective Studies Aged 80 and over Immunosuppression Therapy education.field_of_study business.industry Incidence Retrospective cohort study Middle Aged Prognosis medicine.disease United Kingdom Surgery Cohort Rheumatoid vasculitis Female business Vasculitis Immunosuppressive Agents Follow-Up Studies Systemic vasculitis |
| Zdroj: | Rheumatology. 53:145-152 |
| ISSN: | 1462-0332 1462-0324 |
| DOI: | 10.1093/rheumatology/ket326 |
| Popis: | Objectives. Systemic rheumatoid vasculitis (SRV) is a rare but potentially serious systemic disease manifestation of rheumatoid arthritis (RA) characterized by the development of necrotizing vasculitis. The incidence of SRV appears to be decreasing possibly reflecting progress in RA treatment. The aims of this study were to review the clinical manifestations of SRV in a stable well-defined population during 200110 and to compare with our previous cohort (19882000) and also a cohort from 1975 to 1981. Methods. Using Norfolk Vasculitis Register, a prospective register of patients with systemic vasculitis since 1988, all patients with a diagnosis of SRV from 1 January 2001 until 31 December 2010 were identified. SRV was defined according to the Scott and Bacon criteria (1984). Clinical features were obtained by retrospective case note review. Results. Eighteen patients with SRV were identified (10 male), median age at diagnosis was 72 years and average disease duration 15.6 years. The average annual incidence for 200110 was 3.9 per million. Oneyear mortality was 12% and 5-year mortality 60%. The clinical manifestations were similar apart from systemic and cutaneous features which were more common in the earlier cohorts. Conclusion. The incidence of SRV has declined significantly in the last 40 years; but the clinical manifestations remain similar. Systemic symptoms, and cutaneous manifestations such as infarcts and nodules, are slightly less common in the recent cohort. Despite modern immunosuppressive therapy the prognosis remains poor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|